-
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors
Mfumbilwa, Z. A., Wilschut, J. A., Groen, H. J. M., Retèl, V. P., Ramaekers, B., Joore, M. & Coupé, V. M. H., 2025, (E-pub ahead of print) In: Clinical drug investigation.Research output: Contribution to journal › Article* › Academic › peer-review
-
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
Mfumbilwa, Z. A., Simons, M. J. H. G., Ramaekers, B., Retèl, V. P., Mankor, J. M., Groen, H. J. M., Aerts, J. G. J. V., Joore, M., Wilschut, J. A. & Coupé, V. M. H., Apr 2024, In: PharmacoEconomics. 42, 4, p. 419-434 16 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
Mfumbilwa, Z. A., Wilschut, J. A., Simons, M. J. H. G., Ramaekers, B., Joore, M., Retèl, V., der Welle, C. M.C.-V., Schramel, F. M. N. H., van de Garde, E. M. W. & Coupé, V. M. H., Dec 2023, In: Scientific reports. 13, 1, p. 2349 2349.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
